Dosage and administration
One dose for all your appropriate adult patients
Incorporate CAPVAXIVE into your practice
One dose
0.5-mL prefilled
syringe administered
intramuscularly
Stored in refrigerator
at 2°C to 8°C
(36°F to 46°F)
| CAPVAXIVE can be coadministered with the influenza vaccine |
| See Study 4 for details >> |
Dosage
For intramuscular use.
Administer a single 0.5-mL dose.
Administration
CAPVAXIVE is a colorless, clear to opalescent solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is observed. Administer intramuscularly.
CAPVAXIVE can be coadministered with the influenza vaccine
The OPA responses to CAPVAXIVE administered concomitantly with quadrivalent influenza vaccine were non-inferior to the OPA responses to CAPVAXIVE administered sequentially after influenza vaccine for 20 of 21 serotypes contained in CAPVAXIVE (serotype 23B did not meet non-inferiority criterion). The OPA response to serotype 15B was not assessed for non-inferiority. Influenza vaccine administered concomitantly with CAPVAXIVE was non-inferior to influenza vaccine administered alone as assessed by influenza strain-specific HAI responses for 3 of 4 influenza strains (strain A/H3N2 did not meet non-inferiority criterion). See Study 4 for details >>
Make a strong recommendation for CAPVAXIVE when referring your eligible patients to the pharmacy1
When referring your patients to a pharmacy, direct them to the pharmacy locator tool so they can find CAPVAXIVE at a pharmacy near them. Ask your patients to call their pharmacy ahead to check if they have CAPVAXIVE available.
Who should get CAPVAXIVE?
The CDC recommends adults aged 50 or older receive a pneumococcal vaccination.1
Share with health care professionals
HAI, hemagglutination inhibition; mL, milliliter; OPA, opsonophagocytic activity.
Reference:
- Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1